The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Drew often has issues with Berto over boundaries and the door being locked (at one point, prompting an intervention by Ryan and Amber) and because Berto slept with Natalie (while Amy was visiting Drew). When Drew returns to the room after a few weeks’ absence, Berto suggests the Drew voice his issues while chugging beer; Drew and Berto seem to get along afterwards. Natalie (Lyndon Smith) is Drew's love interest and dorm-mate at UC Berkeley during seasons 5 and 6. Chris Jefferies (Coby Ryan McLaughlin) is Julia's colleague at the law firm where she works during season 6. They dated in law school, and got back in a romantic relationship, until she reconciles with Joel. Before Julia and Joel reconcile, though, Adam recruits Chris for a basketball game during a family picnic where Chris only came to have Julia sign a paper; Joel is mad because she introduced him to the kids. Dr. Leland Gordon (Leland Crooke) is the physician who performs heart surgery on Zeek, and sees him when Zeek has a second cardiac episode. Dylan Jones (Ally Ioannides) is a newer student at Chambers Academy with ADHD and an abrupt personality, who befriends Max (whom she usually calls "Asperger's"). Max becomes romantically interested in her, but she does not reciprocate the feelings that Max has. Aaron Brownstein (Isaac Salzman) is a student at Chambers Academy with ADHD. He is in the culinary arts class, where students are always warning Adam Braverman (who teaches the class) when Aaron has matches or a knife.
== Diagnosis == A seroma may be diagnosed based on signs on the skin. On CT scans, seromas have a radiodensity of 0–20 Hounsfield units, generally in the lower part of this range, consistent with clear fluid.
Nicotinamide riboside kinase 1 is an enzyme that in humans is encoded by the NMRK1 gene. As both a nicotinate riboside kinase (EC 2.7.1.173), and a ribosylnicotinamide kinase (EC 2.7.1.22), this enzyme helps perform a step in the process of converting certain forms of niacin/Vitamin B3 into active coenzymes like NAD+. In humans, nicotinamide riboside kinase 1 is expressed in most tissues of the body, compared to the other isozyme, nicotinamide riboside kinase 2, which is predominantly found in muscles.
=== Research applications === Polyphenol oxidases (PPOs): These include both catechol oxidases and tyrosinases. In additional to research, PPOs have also found applications as biocatalysts. Cystatins are proteins that inhibit cysteine proteases. Research are ongoing to evaluate the potential of using cystatins in crop protection to control herbivorous pests and pathogens.
==== Environmental analysis ==== GC-EI-MS has been successfully used for the determination of pesticide residues in fresh food by a single injection analysis. In this analysis 81 multi-class pesticide residues were identified in vegetables. For this study the pesticides were extracted with dichloromethane and further analyzed using gas chromatography–tandem mass spectrometry (GC–MS–MS). The optimum ionization method can be identified as EI or chemical ionization (CI) for this single injection of the extract. This method is fast, simple and cost effective since high numbers of pesticides can be determined by GC with a single injection, considerably reducing the total time for the analysis.
Sources: en.wikipedia.org
=== X-ray crystal structure determination === The first X-ray crystal structures of tetrahedral intermediates were obtained in 1973 from bovine trypsin crystallized with bovine pancreatic trypsin inhibitor, and in 1974 from porcine trypsin crystallized with soybean trypsin inhibitor. In both cases the tetrahedral intermediate is stabilized in the active sites of enzymes, which have evolved to stabilize the transition state of peptide hydrolysis. Some insight into the structure of tetrahedral intermediate can be obtained from the crystal structure of N-brosylmitomycin A, crystallized in 1967. The tetrahedral carbon C17 forms a 136.54 pm bond with O3, which is shorter than C8-O3 bond (142.31 pm). In contrast, C17-N2 bond (149.06 pm) is longer than N1-C1 bond (148.75 pm) and N1-C11 bond (147.85 pm) due to donation of O3 lone pair into σ* orbital of C17-N2. This model however is forced into tetracyclic sceleton, and tetrahedral O3 is methylated which makes it a poor model overall.
== Structure == Each nerve is covered on the outside by a dense sheath of connective tissue, the epineurium. Beneath this is a layer of fat cells, the perineurium, which forms a complete sleeve around a bundle of axons. Perineurial septa extend into the nerve and subdivide it into several bundles of fibres. Surrounding each such fibre is the endoneurium. This forms an unbroken tube from the surface of the spinal cord to the level where the axon synapses with its muscle fibres, or ends in sensory receptors. The endoneurium consists of an inner sleeve of material called the glycocalyx and an outer delicate meshwork of collagen fibres. Nerves are bundled and often travel along with blood vessels, since the neurons of a nerve have fairly high energy requirements. Within the endoneurium, the individual nerve fibres are surrounded by a low-protein liquid called endoneurial fluid. This acts in a similar way to the cerebrospinal fluid in the central nervous system and constitutes a blood-nerve barrier similar to the blood–brain barrier. Molecules are thereby prevented from crossing the blood into the endoneurial fluid. During the development of nerve edema from nerve irritation (or injury), the amount of endoneurial fluid may increase at the site of irritation. This increase in fluid can be visualized using magnetic resonance (MR) neurography, and thus MR neurography can identify nerve irritation and/or injury.
== Growth conditions == Limnospira platensis has been found in environments with high concentrations of carbonate and bicarbonate. It can also be found in high salt concentrations because of its alkali and salt tolerance. The temperature optimum for this organism is around 35 °C. Based on environmental conditions, culture medium often has a pH between 9–10, inorganic salts, and a high bicarbonate concentration.
In the 1980s and 1990s, Athene Donald's polymer physics lab in Cambridge extensively characterised phase transitions / phase separation of starch granules from the cytoplasm of plant cells, which behave as liquid crystals. In 1991, Pierre-Gilles de Gennes received the Nobel Prize in Physics for developing a generalized theory of phase transitions with particular applications to describing ordering and phase transitions in polymers. Unfortunately, de Gennes wrote in Nature that polymers should be distinguished from other types of colloids, even though they can display similar clustering and phase separation behaviour, a stance that has been reflected in the reduced usage of the term colloid to describe the higher-order association behaviour of biopolymers in modern cell biology and molecular self-assembly.
Sources: en.wikipedia.org
=== Enemies === Wolverine was originally introduced as an antagonist of the Hulk. They have fought multiple times, but also occasionally team up against other foes. Wolverine's archenemy is Sabretooth, who shares the same basic powers and abilities with him. Sabretooth is somewhat older than Logan, and was also a participant in the Weapon X program. Wolverine has also frequently battled Lady Deathstrike, a samurai cyborg whose father invented the process of bonding adamantium to bone. In Japan, Wolverine has fought with Silver Samurai, the half-brother of his lover Mariko. Other prominent enemies include the Hellfire Club and Viper.
==== Desiccated animal thyroid ==== Desiccated thyroid extract is an animal-based thyroid gland extract, most commonly from pigs. It is a combination therapy, containing forms of T4 and T3. It also contains calcitonin (a hormone produced in the thyroid gland involved in the regulation of calcium levels), T1 and T2; these are not present in synthetic hormone medication. This extract was once a mainstream hypothyroidism treatment, but has been disregarded since the 1970s and its use is unsupported by evidence; British Thyroid Association and American professional guidelines discourage its use, as does NICE.
for the 2D (linear) ion trap were also given in literature. There are at least two postulates about the nature of the DC component. The first, of which has been attributed to Ding, assumes for the DIT that the DC component, U depends on not only the mid-level of the AC voltages, V1and V2, but also the duty cycle, d of the waveform:
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.